Personalized antiplatelet therapy: the wrong approach?
Institut de Cardiologie, Inserm U 937, groupe A.C.T.I.O.N., groupe hospitalier Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France. Electronic address: jean-philippe.collet@psl.aphp.fr.
Jean-Philippe
JP
Collet
Gilles
G
Montalescot
D003328:Coronary Thrombosis / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D004351:Drug Resistance; D023381:Endpoint Determination; D006801:Humans; D018579:Patient Selection; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects* / Q000295:instrumentation; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D010979:Platelet Function Tests; D057285:Precision Medicine; D011237:Predictive Value of Tests; D015607:Stents; D016896:Treatment Outcome
D010975:Platelet Aggregation Inhibitors
ACS; Acute coronary syndrome; Angioplastie coronaire; Antiplatelet therapy; CABG; CI; HR; NSTE-ACS; PCI; Percutaneous coronary intervention; Syndrome coronaire aigu; Traitement antiplaquettaire; acute coronary syndrome; confidence interval; coronary artery bypass graft; hazard ratio; non-ST-segment elevation acute coronary syndrome; percutaneous coronary intervention.